|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nadolol#Adverse Reactions]] |
| {{Nadolol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| Most adverse effects have been mild and transient and have rarely required withdrawal of therapy.
| |
| | |
| ===Cardiovascular===
| |
| [[Bradycardia]] with heart rates of less than 60 beats per minute occurs commonly, and heart rates below 40 beats per minute and/or symptomatic bradycardia were seen in about 2 of 100 patients. Symptoms of peripheral vascular insufficiency, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. [[Cardiac failure]], hypotension, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree heart block have been reported; intensification of AV block is a known effect of beta-blockers (see also CONTRAINDICATIONS, WARNINGS, andPRECAUTIONS).
| |
| | |
| ===Central Nervous System===
| |
| [[Dizziness]] or fatigue has been reported in approximately 2 of 100 patients; paresthesias, sedation, and change in behavior have each been reported in approximately 6 of 1000 patients.
| |
| | |
| ===Respiratory===
| |
| Bronchospasm has been reported in approximately 1 of 1000 patients (see CONTRAINDICATIONS and WARNINGS).
| |
| | |
| ===Gastrointestinal===
| |
| [[Nausea]], [[diarrhea]], abdominal discomfort, constipation, vomiting, indigestion, [[anorexia]], [[bloating]], and [[flatulence]] have been reported in 1 to 5 of 1000 patients.
| |
| | |
| ===Miscellaneous===
| |
| Each of the following has been reported in 1 to 5 of 1000 patients: rash; [[pruritus]]; headache; dry mouth, eyes, or skin; impotence or decreased libido; facial swelling; weight gain; slurred speech; cough; nasal stuffiness; sweating; tinnitus; blurred vision. Reversible alopecia has been reported infrequently.
| |
| | |
| The following adverse reactions have been reported in patients taking nadolol and/or other beta-adrenergic blocking agents, but no causal relationship to nadolol has been established.
| |
| | |
| ===Central Nervous System===
| |
| Reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability with slightly clouded sensorium, and decreased performance on neuropsychometrics.
| |
| | |
| ===Gastrointestinal===
| |
| Mesenteric arterial thrombosis; [[ischemic colitis]]; elevated liver enzymes.
| |
| | |
| ===Hematologic===
| |
| [[Agranulocytosis]]; [[thrombocytopenic]] or nonthrombocytopenic [[purpura]].
| |
| | |
| ===Allergic===
| |
| | |
| [[Fever]] combined with aching and sore throat; [[laryngospasm]]; [[respiratory distress]].
| |
| | |
| ===Miscellaneous===
| |
| | |
| Pemphigoid [[rash]]; hypertensive reaction in patients with [[pheochromocytoma]]; sleep disturbances; [[Peyronie's disease]].
| |
| | |
| The [[oculomucocutaneous syndrome]] associated with the beta-blocker practolol has not been reported with nadolol.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INDERAL LA (PROPRANOLOL HYDROCHLORIDE) CAPSULE, EXTENDED RELEASE [AKRIMAX PHARMACEUTICALS, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2e709d2-96a2-41ea-b5e9-9ce4ccb91f59 | publisher = | date = |accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |